Malignant Melanoma: Molecular Diagnostics, Emerging Therapies, and the Microbiome

The presentation delves into the complexities of malignant melanoma, emphasizing the genetic evolution of melanocytic tumors and the significance of molecular diagnostics and emerging therapies. It highlights the continuum of genetic alterations leading to melanoma, showcasing various types of melanocytic nevi, such as blue nevi and common acquired nevi, orchestrated by specific oncogenes like BRAF and RAS mutations. The discussion covers the diagnostic challenges posed by atypical Spitz tumors and emphasizes the need for advanced genetic profiling to better classify these lesions and tailor therapeutic strategies. Several case studies illustrate how genetic mutations influence tumor behavior and treatment options, including the use of targeted therapies such as MEK and ALK inhibitors. The potential role of the microbiome in melanoma pathogenesis is noted, alongside the importance of immunotherapy in current treatment regimens. Overall, the talk underscores the dynamic interplay between genetic drivers, tumor morphology, and therapy choices, advocating for an integrative approach to enhance patient outcomes in melanoma management.